Robert Casey actually said...

"But my question is, why stop at insulin?"

"It will be a huge issue among many difficult issues in this reauthorization."

"We need it and we need notification both with drugs and devices, not only when manufacturing is disrupted, but also when there is a huge surge in demand."

"We learned a horrible lesson in the pandemic, which--and the way I look at it, kind of a national failure when we couldn't provide the kind of PPE that we needed."